p53 protein expression in patients with hepatocellular carcinoma from the high incidence area of Guangxi: Southern China

Cancer Letters

Volumn 121, Issue 2, 1997, Pages 203-210

  Qin, Guozhong ^a   Su, Jianjia ^a   Ning, Yaoyu ^a   Duan, Xiaoxian ^b   Luo, Dan ^b   Lotlikar, Prabhakar D ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Guangxi Cancer Institute   (China)

Author keywords

Aflatoxin B1; Hepatitis B; Hepatocellular carcinoma; p53 expression

Indexed keywords

AFLATOXIN B1; ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN; PROTEIN P53;

ADULT; AGE; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CELL DIFFERENTIATION; CHINA; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; GENE MUTATION; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; CARCINOMA, HEPATOCELLULAR; CHINA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

HEPATITIS B VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 0031443212     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00352-2     Document Type: Article

References (46)

1. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 Mutation in human cancer. Science. 253:1991;49-53.
2. Miller C., Mohandas T., Wolf D., Prokocimer M., Rotter V., Koeffler H.P. Human p53 gene localized to short arm of chromosome 17. Nature. 319:1986;783-784.
3. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
4. Soussi T., Legros Y., Lubin R., Ory K., Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer. 57:1994;1-9.
5. Challen C., Lunec J., Warren W., Collier J., Bassendine M.F. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinoma from Britain. Hepatology. 16:1992;1362-1366.
6. Laurent-Puig P., Flejou J.F., Fabre M., Bedossa P., Belghiti J., Gayral F., Franco D. Overexpression of p53: a rare event in a large series of white patients with hepatocellular carcinoma. Hepatology. 16:1992;1171-1175.
7. Cattoretti G., Rilke F., Andrealo S., D'Amato L., Delia D. p53 Expression in breast cancer. Int. J. Cancer. 41:1988;178-183.
8. Costa A., Marasca R., Valentinis B., Savarino M., Faranda A., Silvestrini R., Torelli G. p53 Gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J. Pathol. 176:1995;45-53.
9. Goldblum J.R., Bartos R.E., Carr K.A., Frank T.S. Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. Am. J. Surg. Pathol. 17:1993;1244-1251.
10. Ng I.O.L., Srivastava G., Chung L.P., Tsang S.W.Y., Ng M.M.T. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinoma in Hong Kong people. Cancer. 74:1994;30-37.
11. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancer in 1985. Int. J. Cancer. 54:1993;594-606.
12. Simonetti R.G., Camma F., Politi F., Damico G., Pagliaro L. Hepatocellular carcinoma: a world wide problem and the major risk factors. Dig. Dis. Sci. 36:1991;962-972.
13. Yeh F.S., Shen K.N. Epidemiology and early diagnosis of primary liver cancer in China. Adv. Cancer Res. 47:1986;297-329.
14. Groopman J.D., Zhu J., Donahue P.R., Pikul A., Zhang L., Chen J.S., Wogan G.N. Molecular dosimetry of urinary aflatoxix-DNA adducts in people living in Guangxi autonomous region, People's Republic of China. Cancer Res. 52:1992;45-52.
15. Okuno H., Xie Z.C., Lu B.Y., Qin X., Takasu M., Kano H., Shiozaki Y., Inoue K. A low prevalence of anti-hepatitis C virus antibody in patients with hepatocellular carcinoma in Guangxi province, Southern China. Cancer. 73:1994;58-62.
16. Yeh F.S., Yu M.C., Mo C.C., Luo S., Tong M.J., Henderson B.E. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in Southern Guangxi, China. Cancer Res. 49:1989;2506-2509.
17. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutation of p53 gene in hepatocellular carcinoma from Southern Africa. Nature. 350:1991;429-431.
18. Coursaget P., Depril N., Chabaud M., Nandi R., Mayelo V., LeCann P., Yvonnet B. High prevalence of mutations at codon 249 of the gene in hepatocellular carcinoma from Senegal. Br. J. Cancer. 67:1993;1395-1397.
19. Hsia C.C., Kleiner D.E. Jr., Axiotis C.A., Bisceglie A.D., Nomura A.M., Stemmermann G.N., Tabor E. Mutations of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. J. Natl. Cancer Inst. 84:1992;1638-1641.
20. Ozturk M.et al. p53 Mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 338:1991;1356-1359.
21. Tanaka S., Toh Y., Adachi E., Matsumata T., Mori R., Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res. 53:1993;2884-2887.
22. Unsal H., Yakicier C., Marcais C., Kew M., Volkmann M., Zentgraf H., Isselbacher K.J., Ozturk M. Genetic heterogeneity of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA. 91:1994;822-826.
23. Edmondson H.A., Steiner P.E. Primary carcinoma of the liver. A study of 100 cases among 48 900 necropsies. Cancer. 7:1954;462-503.
24. Resnick J.M., Cheuwitz D., Knapp D., Uhlman D., Niehans G.A. A microwave method that enhances detection of aberrant p53 expression in formalin-fixed paraffin-embedded tissues. Arch. Pathol. Lab. Med. 119:1995;360-366.
25. Buendia M.A. Hepatitis B virus and hepatocellular carcinoma. Adv. Cancer Res. 59:1992;167-226.
26. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinoma. Nature. 350:1991;427-428.
27. Hayashi H., Sugio K., Matsumata T., Adachi E., Takenaka K., Sugimachi K. The clinical significance of p53 gene mutation in hepatocellular carcinoma from Japan. Hepatology. 22:1995;1702-1707.
28. Hosono S., Chou M.J., Lee C.S., Shih C. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene. 8:1993;491-496.
29. Hsu H.C., Tseng H.J., Lai P.L., Lee P.H., Peng S.Y. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res. 53:1993;4691-4694.
30. Nagao T., Kondo F., Sato T., Nagato Y., Kondo Y. Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: correlation with cell proliferative activity indices, including mitotic index and MIB-1 immunostaining. Hum. Pathol. 26:1995;326-333.
31. Hayward N.K., Walker G.T., Graham W., Cooksley E. Hepatocellular carcinoma mutation. Nature. 352:1991;29.
32. Shieh Y.S.C., Nguyen C., Vocal M.V., Chu H.W. Tumor-suppressor p53 gene in hepatitis C and B virus-associated human hepatocellular carcinoma. Int. J. Cancer. 54:1993;558-562.
33. Scorsone K.A., Zhou Y.Z., Butel J.S., Slagle B.L. p53 Mutation cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinoma from China. Cancer Res. 52:1992;1635-1638.
34. Ojanguren I., Ariza A., Castella E.M., Fernandez-Vasalo A., Mate J.L., Navas-Palacios J.J. p53 Immunoreactivity in hepatocellular adenoma, focal nodular hyperplasia, cirrhosis and hepatocellular carcinoma. Histopathology. 26:1995;63-68.
35. Wee A., Teh M., Raju G.C. p53 Expression in hepatocellular carcinoma in a population in Singapore with endemic hepatitis B virus infections. J. Clin. Pathol. 48:1995;236-238.
36. Soini Y., Chia S.C., Bennett W.P., Groopman J.D., Wang J.S., DeBenedetti V.M.G., Cawley H., Welsh J.A., Hansen C., Bergasa N.V., Jones E.A., DiBisceglie A.M., Trivers G.E., Sandoval C.A., Calderon I.E., Munoz Espinosa L.E., Harris C.C. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinoma from Mexico. Carcinogenesis. 17:1996;1007-1012.
37. Schaff Z.S., Sarosi I., Hsia C.C., Kiss A., Tabor E. p53 In malignant and benign liver lesions. Eur. J. Cancer. 31A:1995;1847-1850.
38. Volkmann M., Hofmann W.J., Müller M., Rath U., Otto G., Zentgraf H., Galle P.R. p53 Overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene. 9:1994;195-204.
39. Murakami Y., Hayashi K., Hirohashi S., Sekiya T. Aberrations of tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51:1991;5520-5525.
40. Aguilar F., Harris C.C., Sun T., Hollstein M., Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science. 264:1994;1317-1319.
41. Livni N., Eid A., Ilan Y., Rivkinda A., Rosenmann E., Blendis L.M., Shouval D., Galun E. p53 Expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer. 75:1995;2420-2426.
42. 1. J. Cancer Res. Clin. Oncol. 122:1996;289-295.
43. Bourdon J.C., D'Errico A., Paterlini G.W., May E., Debuire B. p53 Protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology. 108:1995;1176-1182.
44. Coles C., Condie A., Chetty U., Steel C.M., Evans H.J., Prosser J. p53 Mutation in breast cancer. Cancer Res. 52:1992;5291-5298.
45. 1. Proc. Natl. Acad. Sci. USA. 80:1983;2695-2698.
46. Puisieux A., Lim S., Groopman J., Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 51:1991;6185-6189.